Citadel Advisors
ARQT icon

Citadel Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

Citadel Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.4M Buy
1,160,014
+1,144,408
+7,333% +$26.7M ﹤0.01% 2082
2026
Q1 		$368K Sell
15,606
-139,552
-90% -$3.56M ﹤0.01% 10004
2025
Q4 		$4.51M Sell
155,158
-22,110
-12% -$566K ﹤0.01% 4444
2025
Q3 		$3.34M Buy
177,268
+31,775
+22% +$501K ﹤0.01% 5110
2025
Q2 		$2.04M Sell
145,493
-164,582
-53% -$2.31M ﹤0.01% 5666
2025
Q1 		$4.85M Buy
310,075
+220,907
+248% +$3.11M ﹤0.01% 3926
2024
Q4 		$1.24M Sell
89,168
-2,941,905
-97% -$32.2M ﹤0.01% 6577
2024
Q3 		$28.2M Buy
3,031,073
+98,426
+3% +$971K 0.01% 1730
2024
Q2 		$27.3M Buy
2,932,647
+1,018,377
+53% +$9.21M 0.01% 1691
2024
Q1 		$19M Buy
+1,914,270
New +$14.3M ﹤0.01% 2122
2023
Q4 		– Sell
-250,535
Closed -$681K – 14228
2023
Q3 		$1.33M Buy
250,535
+196,127
+360% +$1.67M ﹤0.01% 6005
2023
Q2 		$519K Sell
54,408
-217,113
-80% -$2.41M ﹤0.01% 7855
2023
Q1 		$2.99M Buy
271,521
+261,888
+2,719% +$3.79M ﹤0.01% 4639
2022
Q4 		$143K Sell
9,633
-70,882
-88% -$1.24M ﹤0.01% 10684
2022
Q3 		$1.54M Sell
80,515
-111,996
-58% -$2.54M ﹤0.01% 6105
2022
Q2 		$4.1M Buy
192,511
+15,811
+9% +$324K ﹤0.01% 4163
2022
Q1 		$3.4M Sell
176,700
-70,215
-28% -$1.19M ﹤0.01% 4923
2021
Q4 		$5.12M Sell
246,915
-19,017
-7% -$379K ﹤0.01% 4246
2021
Q3 		$6.35M Sell
265,932
-175,580
-40% -$4M ﹤0.01% 3857
2021
Q2 		$12M Sell
441,512
-10,944
-2% -$308K ﹤0.01% 2800
2021
Q1 		$13.1M Buy
452,456
+318,753
+238% +$9.95M ﹤0.01% 2577
2020
Q4 		$3.76M Buy
133,703
+118,353
+771% +$2.9M ﹤0.01% 4181
2020
Q3 		$450K Sell
15,350
-17,739
-54% -$474K ﹤0.01% 7479
2020
Q2 		$1M Sell
33,089
-22,476
-40% -$650K ﹤0.01% 5826
2020
Q1 		$1.66M Buy
+55,565
New +$1.49M ﹤0.01% 4454

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors's ARQT Position: Q2 2026 in Review

Citadel Advisors increased its Arcutis Biotherapeutics (ARQT) stake by 7,333% in Q2 2026, buying an estimated $26.7M and bringing the position to 1,160,014 shares worth $30.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2082.

Citadel Advisors first reported a position in ARQT in Q1 2020 and has held it in 25 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Citadel Advisors held 1,160,014 shares of Arcutis Biotherapeutics worth $30.4M as of Q2 2026.
  • Citadel Advisors bought 1,144,408 Arcutis Biotherapeutics shares in Q2 2026, an estimated $26.7M.
  • Arcutis Biotherapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2082 holding.
  • Citadel Advisors first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 25 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.